RNAi Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Micro RNA, Small interfering RNA, Others), By Application (Treatment Type, Therapeutics, Drug Delivery, Agriculture, Others), By End User (Research and Academic Laboratories, Diagnostic Laboratories, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.61 Billion
CAGR (2026-2031)	10.87%
Fastest Growing Segment	Agriculture
Largest Market	North America
Market Size (2031)	USD 2.99 Billion

Market Overview

The Global RNAi Technology Market will grow from USD 1.61 Billion in 2025 to USD 2.99 Billion by 2031 at a 10.87% CAGR. The Global RNAi Technology Market encompasses therapeutics and research tools utilizing RNA interference mechanisms to neutralize targeted mRNA molecules, thereby inhibiting gene expression to treat genetic disorders, viral infections, and malignancies. The market is primarily driven by the rising prevalence of chronic diseases and the growing demand for precision medicine that can address previously undruggable targets. Additionally, sustained improvements in drug delivery systems, particularly lipid nanoparticle formulations, are enhancing the stability and bioavailability of these therapeutics, which supports their wider clinical adoption.

However, the difficulty of delivering RNA molecules to tissues beyond the liver remains a significant challenge that restricts the therapeutic scope of current technologies. Ensuring stability in the bloodstream and cellular uptake without inducing off-target immune responses continues to complicate development timelines. According to the American Society of Gene & Cell Therapy, in 2025, the RNA therapy pipeline expanded as 38 new clinical trials were initiated in the second quarter, demonstrating the industry's persistent investment in overcoming these translational hurdles.

Key Market Drivers

The rising prevalence of cancer and chronic infectious diseases is a primary catalyst propelling the Global RNAi Technology Market. As conventional therapeutic modalities often fail to address complex genetic drivers, RNA interference offers a unique mechanism to silence specific disease-causing genes with high precision. This critical demand is underscored by the escalating disease burden; according to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025' report, it was projected that over 2 million new cancer cases would be diagnosed in the United States in 2025. Consequently, the capacity of RNAi therapeutics to engage previously undruggable targets positions them as vital tools for future oncology and infectious disease treatment regimens.

Strategic collaborations and licensing agreements in the life sciences sector are further accelerating market expansion by providing the necessary capital to advance clinical pipelines. Major pharmaceutical entities are increasingly partnering with specialized biotech firms to leverage proprietary platforms and mitigate development risks. For instance, according to GeneOnline, September 2025, in the 'Novartis Allocates Additional $5.2 Billion to RNAi Cardiovascular Therapy Partnership with Argo Biopharma' article, Novartis committed an additional $5.2 billion to its collaboration with Argo Biopharma to develop RNAi therapies for cardiovascular conditions. These alliances are successfully translating R&D into commercial reality; according to Arrowhead Pharmaceuticals, in 2025, the U.S. FDA approved plozasiran, a novel RNAi therapeutic for familial chylomicronemia syndrome, highlighting the sector's continued commercial progress.

Download Free Sample Report

Key Market Challenges

The inability to efficiently deliver RNA molecules to tissues beyond the liver constitutes a formidable barrier hampering the expansion of the Global RNAi Technology Market. While current technologies have achieved success in hepatic targets, the market is severely constrained by the challenge of engineering delivery vehicles that can navigate to organs such as the brain, heart, or lungs without degrading or triggering toxicity. This technical limitation restricts the commercial scope of RNAi therapeutics to a narrow range of indications, effectively capping the addressable market and preventing entry into high-demand therapeutic areas like neurology and broad-spectrum oncology.

Consequently, the complexity of ensuring bloodstream stability and preventing off-target immune responses has introduced significant friction into the drug development process. These translational hurdles increase the risk profile of new candidates, leading to extended development timelines and cautious clinical progression. The impact of these barriers is evident in recent industry metrics. According to the American Society of Gene & Cell Therapy, clinical development activity slowed across the broader gene, cell, and RNA landscape in the third quarter of 2025, with total trial initiations dropping to 125 following the previous quarter's surge. This contraction highlights how delivery-related difficulties directly throttle the pipeline's velocity and delay market maturation.

Key Market Trends

The Commercialization of RNAi-Based Biopesticides and Agricultural Solutions is fundamentally diversifying the market beyond human therapeutics by addressing critical challenges in crop protection. This trend leverages the specificity of RNA interference to silence essential genes in pests without harming beneficial insects or the environment, offering a sustainable alternative to conventional chemical agents. Industry players are increasingly securing capital to advance these eco-friendly platforms from the laboratory to field trials. For instance, according to Renaissance BioScience, September 2025, in the 'Renaissance BioScience Receives Government of Canada Funding to Target Destructive Canola Flea Beetle Crop Pests' press release, the company secured CAN$830,000 to accelerate the development of its proprietary RNAi biocontrol technology for the agriculture sector.

Increasing Reliance on CDMOs for Scalable Oligonucleotide Manufacturing is simultaneously emerging as a structural shift to support the mass production of RNAi therapeutics. As the pipeline expands into high-prevalence indications, developers are externalizing production to specialized contract organizations that offer the advanced capacity and regulatory expertise required for commercial volumes. This strategic outsourcing allows pharmaceutical firms to mitigate technical manufacturing risks and accelerate supply chain readiness for large-scale patient populations. Underscoring this expansion, according to Bachem, July 2025, in the 'Bachem shows strong growth in the first half of 2025' report, the company invested CHF 129.1 million in the first half of the year specifically to expand production capacity across its global site network.

Segmental Insights

The agriculture segment represents the fastest-growing category in the global RNAi technology market, primarily driven by the increasing adoption of RNA-based biopesticides for sustainable crop protection. This technology allows for the silencing of specific genes in pests, offering a precise alternative to chemical pesticides that minimizes harm to non-target species. The expansion is further accelerated by favorable assessments from regulatory bodies, such as the United States Environmental Protection Agency, which have established pathways for approving these biological solutions. Consequently, agricultural stakeholders are rapidly integrating RNA interference methods to manage pest resistance and reduce environmental impact.

Regional Insights

North America maintains a dominant position in the global RNAi technology market, driven by significant investment in pharmaceutical research and development. The region benefits from a favorable regulatory environment, where the United States Food and Drug Administration has proactively approved various RNA interference therapeutics. Additionally, robust healthcare infrastructure and consistent funding for genomic studies facilitate the rapid commercialization of these treatments. This strong ecosystem supports extensive clinical trials and strategic industry collaborations, ensuring North America remains the primary hub for advancements in RNAi applications.

Recent Developments

• In September 2024, Arrowhead Pharmaceuticals announced successful results from the Phase 3 PALISADE study of plozasiran, an investigational RNAi medicine for familial chylomicronemia syndrome. The data showed that the treatment achieved a statistically significant reduction in fasting triglyceride levels by approximately 80% compared to placebo. Furthermore, the study demonstrated a substantial decrease in the incidence of acute pancreatitis, a key clinical risk for patients with this rare genetic disorder. Based on these findings, the company confirmed its intention to file a New Drug Application with regulatory authorities to bring this potential first-in-class therapy to market.
• In August 2024, Alnylam Pharmaceuticals presented detailed positive results from the Phase 3 HELIOS-B study of vutrisiran, an investigational RNAi therapeutic for the treatment of ATTR amyloidosis with cardiomyopathy. The data, shared at the European Society of Cardiology Congress, demonstrated that the drug significantly reduced the risk of all-cause mortality and recurrent cardiovascular events in patients. The study met all primary and secondary endpoints, reinforcing the potential of this quarterly subcutaneous injection to become a new standard of care. Following these results, the company prepared to submit regulatory filings to expand the label for this therapy.
• In February 2024, Silence Therapeutics announced the receipt of a $10 million milestone payment from its ongoing collaboration with AstraZeneca. This payment was triggered by the initiation of a Phase 1 clinical trial for the first product candidate developed under their multi-target partnership. The collaboration utilizes Silence’s proprietary mRNAi GOLD™ platform to discover and develop small interfering RNA (siRNA) therapeutics aimed at cardiovascular, renal, metabolic, and respiratory diseases. The companies originally established this strategic alliance to combine Silence’s precision-engineered medicine capabilities with AstraZeneca’s extensive expertise in disease biology and global commercialization.
• In January 2024, Novartis entered into two exclusive license and collaboration agreements with Argo Biopharma to develop RNA interference (RNAi) therapies for cardiovascular diseases. Under the terms of the deal, the Swiss pharmaceutical giant agreed to pay an upfront sum of $185 million to the Shanghai-based biotechnology company. The collaboration, which grants Novartis global rights to specific clinical-stage programs, holds a potential total value of up to $4.165 billion including option fees, development milestones, and commercial payments. This strategic partnership aims to leverage Argo’s proprietary platform to address unmet medical needs in heart health.

Key Market Players

• Alnylam Pharmaceuticals, Inc
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics Inc.
• Phio Pharmaceuticals Corp.
• Benitec Biopharma Ltd.
• Novartis AG
• AstraZeneca PLC
• Silence Therapeutics Plc.
• Arbutus Biopharma Corp.
• Sylentis S.A.

By Type	By Application	By End User	By Region
Micro RNA Small interfering RNA Others	Treatment Type Therapeutics Drug Delivery Agriculture Others	Research and Academic Laboratories Diagnostic Laboratories Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global RNAi Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• RNAi Technology Market, By Type:

• Micro RNA
• Small interfering RNA
• Others

• RNAi Technology Market, By Application:

• Treatment Type
• Therapeutics
• Drug Delivery
• Agriculture
• Others

• RNAi Technology Market, By End User:

• Research and Academic Laboratories
• Diagnostic Laboratories
• Others

• RNAi Technology Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE